Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2013

01-08-2013 | Systematic Review

Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review

Authors: Jenny Lingman-Framme, Anders Fasth

Published in: Drugs | Issue 12/2013

Login to get access

Abstract

Background

Substitution with immunoglobulin can be administered intravenously (IV) or subcutaneously (SC) to patients with immunodeficiency, but it is not clear which route is to be preferred.

Objective

The aim of this study was to compare IV and SC administration of immunoglobulin regarding efficacy, safety, health-related quality of life and health economics in patients with primary or secondary immunodeficiency.

Method

PubMed and other databases were searched. Reference lists of retrieved articles were scanned and major immunoglobulin producers were contacted for additional articles. Randomized and non-randomized clinical studies that compared SC with IV immunoglobulin substitution in patients with immunodeficiency were included. The validity of the findings in the included studies was evaluated and summarized in accordance with the GRADE approach.

Results

Twenty-five studies were included; two randomized and 17 non-randomized studies of patients with primary immunodeficiency, one non-randomized study of patients with secondary immunodeficiency and five studies of health economics. The quality of evidence as assessed by the GRADE score was found to be moderate or low for all outcomes. Both IV and SC administration of immunoglobulin was found to be highly effective in preventing serious bacterial infections. IgG trough levels were higher with SC immunoglobulin substitution. Both therapy forms were concluded to be safe, as no serious adverse event was reported. Minor adverse events, consisting of local symptoms that were usually mild, were more frequent with SC immunoglobulin substitution. Health-related quality of life improved when patients switched from hospital-based IV immunoglobulin substitution to SC immunoglobulin substitution at home. The studies that evaluated health economics all found that SC administration was considerably more cost effective in comparison with IV immunoglobulin substitution. The main difference was that the number of lost work or school days was lower in patients with SC administration.

Conclusion

Both SC and IV immunoglobulin substitution offer protection from serious bacterial infections and have good safety. On the basis of available studies it is not possible to rate one of the two substitution modes as superior to the other, at least not regarding efficacy and safety. Improvement of health-related quality of life with SC immunoglobulin substitution largely seems to be related to home therapy. Studies including patients with secondary immunodeficiency were few, as were randomized studies of patients with primary immunodeficiency.
Literature
1.
Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:417–32.PubMedCrossRef
2.
3.
4.
5.
Eijkhout HW, van der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135:165–74.PubMedCrossRef
6.
Ochs HD, Fischer SH, Wedgwood RJ, et al. Comparison of high dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med. 1984;76:78–82.PubMedCrossRef
7.
Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1:1075–7.PubMedCrossRef
8.
Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol. 1994;1:613–9.PubMed
9.
Gardulf A, Hammarström L, Smith CI. Home treatment of hypogamma-globulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRef
10.
11.
12.
13.
14.
Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. BMJ. 1994;308:581–5.PubMedCrossRef
15.
Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. J Clin Immunol. 2004;112:1–7.CrossRef
16.
Chinen J, Shearer WT. Subcutaneous immunoglobulins: alternative for the hypogammaglobulinemic patient? J Allergy Clin Immunol. 2004;114:934–5.PubMedCrossRef
17.
Busse J, Hoffman F, Schlieben S, et al. Subcutaneous immunoglobulin substitution in primary B-cell defects. Review of the literature and experiences with 17 patients over a period of 6 years [in German]. Tagliche Praxis. 2005;46:185–92.
18.
Chouksey A, Duff K, Wasserbauer N, et al. Subcutaneous immunoglobulin-G replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005;1:120–30.PubMed
19.
Durandy A, Wahn V, Petteway S, et al. Immunoglobulin replacement therapy in primary antibody deficiency diseases: maximizing success. Int Arch Allergy Immunol. 2005;136:217–29.PubMedCrossRef
20.
Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434–42.PubMedCrossRef
21.
22.
Helbert M, Farragher A. Subcutaneous immunoglobulin for patients with antibody deficiency. Br J Hosp Med (Lond). 2007;68:206–10.
23.
24.
Berger M. Principles and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28:413–37.CrossRef
25.
Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Am. 2008;28:803–19.CrossRef
26.
Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21.PubMedCrossRef
27.
Stiehm ER, Keller MA, Vyas GN. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals. 2008;36:363–74.PubMedCrossRef
28.
Kirmse J. The nurse’s role in intravenous immunoglobulin therapy. Home Healthc Nurse. 2009;27:104–11.PubMedCrossRef
29.
Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158:51–9.PubMedCrossRef
30.
Moore ML, Quinn JM. Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency. Ped Health. 2009;3:231–40.CrossRef
31.
Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:182–94.CrossRef
32.
Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11:532–8.PubMedCrossRef
33.
Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol. 2011;22:758–69.PubMedCrossRef
34.
Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396–404.PubMedCrossRef
35.
Misbah S, Kuijpers T, van der Heijden J, et al. Bringing immunoglobulin knowledge up to date: how should we treat today? Clin Exp Immunol. 2011;166:16–25.PubMedCrossRef
36.
Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7:301–16.PubMedCrossRef
37.
Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180–92.PubMedCrossRef
38.
Borte M, Baumann U, Pittrow D, et al. Immunoglobulins in PID, SID and neurological autoimmune disease [in German]. Dtsch Med Wochenschr. 2012;137:675–80.PubMedCrossRef
39.
Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46:315–21.PubMedCrossRef
40.
Hernandez-Trujillo HS, Chapel H, Lo Re V, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169:57–69.PubMedCrossRef
41.
Kobrinsky L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277–87.
42.
Atkins D, Best D, Briss PA, GRADE Working Group, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490–4.PubMedCrossRef
43.
Schünemann H, Brożek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 (updated March 2009). The GRADE Working Group, 2009. Available from http://​www.​cc-ims.​net/​gradepro.
44.
45.
46.
47.
Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365–9.PubMedCrossRef
48.
Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.PubMedCrossRef
49.
Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.PubMedCrossRef
50.
Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.PubMedCrossRef
51.
Högy B, Keinecke H, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6:24–9.PubMedCrossRef
52.
Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.PubMedCrossRef
53.
Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies: a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.PubMedCrossRef
54.
Haddad L, Perrinet M, Parent D, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution [in French]. Rev Med Interne. 2006;27:924–6.PubMedCrossRef
55.
Kittner JM, Grimbacher B, Wulff W, et al. Patients’ attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26:400–5.PubMedCrossRef
56.
Ochs HD, Gupta S, Kiessling P, Subcutaneous IgG Study Group, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.PubMedCrossRef
57.
Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474–8.PubMedCrossRef
58.
Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.PubMedCrossRef
59.
Desai SH, Chouksey A, Poll J, et al. Pilot study of equal doses of 10 % IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124:854–6.PubMedCrossRef
60.
Maroto Hernando M, Soler Palacín P, Martin Nalda N, et al. Subcutaneous gammaglobulin in common variable immunodeficiency: first experience in Spain [in Spanish]. An Pediatr 2009;70:111–9.
61.
Beauté J, Levy P, Millet V, French PID study group CEREDIH, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160:240–5.PubMedCrossRef
62.
Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238–45.PubMed
63.
Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. Clin Immunol. 2010;30:301–7.CrossRef
64.
Wasserman RL, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.PubMedCrossRef
65.
Jolles S, Bernatowska E, de Gracia J, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141:90–102.PubMedCrossRef
66.
Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10 % liquid immune globulin preparation (GAMMAGARD LIQUID, 10 %) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323–31.PubMedCrossRef
67.
Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50:405–11.PubMedCrossRef
68.
Sundin M, Nordin K, Jostemyr Y, et al. Subcutaneous IgG replacement after pediatric SCT. Pediatric Transpl. 2012;16:866–71.CrossRef
69.
Wasserman RL, Melamed I, Stein MR, et al. IGSC, 10 % with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130:951–7.PubMedCrossRef
70.
Martin A, Lavoie L, Goetghebeur M, et al. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23:55–60.PubMedCrossRef
71.
Ducruet T, Levasseur MC, Des Roches A, et al. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013;131:585–7.PubMedCrossRef
72.
Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525–53.PubMedCrossRef
73.
Gennery AR, Slatter MA, Grandin L, on behalf of members of European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency, et al. Long term survival and transplantation of haematopoietic stem cells for primary immunodeficiencies: report of the European experience 1968–2005. J Allergy Clin Immunol. 2010;126:602–10.PubMedCrossRef
74.
Eapen M, Ahn KW, Orchard PJ, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transpl. 2012;18:1438–45.CrossRef
75.
Caress JB, Hobson-Webb L, Passmore LV. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009;256:339–42.PubMedCrossRef
76.
Al-Riyami AZ, Lee J, Connolly M, et al. Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura. Pediatr Blood Cancer. 2011;57:157–9.PubMedCrossRef
77.
78.
79.
Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.PubMedCrossRef
80.
Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169:172–81.PubMedCrossRef
81.
Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33:984–90.PubMedCrossRef
82.
Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol. 2013;33:49–54.PubMedCrossRef
Metadata
Title
Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review
Authors
Jenny Lingman-Framme
Anders Fasth
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0094-3

Other articles of this Issue 12/2013

Drugs 12/2013 Go to the issue

Therapy in Practice

Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure

Adis Drug Evaluation

Zonisamide: A Review of Its Use in the Management of Adults with Partial Seizures

Adis Drug Evaluation

Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine

Review Article

Treatment of Opioid-Induced Constipation: Focus on the Peripheral μ-Opioid Receptor Antagonist Methylnaltrexone

Review Article

Extra-Esophageal Manifestations of Gastroesophageal Reflux Disease: Diagnosis and Treatment

Adis Drug Evaluation

Recombinant Trivalent Influenza Vaccine (Flublok®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults